Mois : août 2020

The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer, Oliviero Marinelli et al., 2020,

The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer Oliviero Marinelli, Maria Beatrice Morelli, Daniela Annibali, Cristina Aguzzi, Laura Zeppa, Sandra Tuyaerts, Consuelo Amantini, Frédéric Amant, Benedetta Ferretti, Federica Maggi, Giorgio Santoni, Massimo Nabissi International Journal of Molecular Sciences, 2020, 21, 5409 doi : 10.3390/ijms21155409   Abstract : Several studies support, both in vitro and in vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated in tumors, is associated with altered cell proliferation and aggressiveness. Endometrial cancer (EC) is historically divided in type I endometrioid EC and type II non-endometrioid EC, associated with [...]

Lire la suite

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation, Ralph Ellis, 2020

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation Ralph Ellis Medscape, August 21, 2020 The US Food and Drug Administration has approved phase one clinical trials for a synthetic cannabinoid drug designed to treat acute respiratory distress syndrome (ARDS), a life-threatening lung condition which may occur in severe cases of the novel coronavirus, Forbes reported. ARDS can be triggered by over-creation of cytokines, proteins which tell the body to produce more inflammation, Forbes said. The drug going to clinical trials, ARDS-003, would “dampen the cytokine release" and prevent development of ARDS, Tetra Bio-Pharma company CEO and chief regulatory officer Guy Chamberland, MD, [...]

Lire la suite